Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...

A prospective survey study presented at the 2026 ASCO Annual Meeting highlighted the heterogeneity of patient experiences ...

At the American Society of Clinical Oncology (ASCO) meeting, phase II findings suggested that intratumoral dendritic cell ...

Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic ...

In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January-June 2026 April-June 2026 Highlights Net sales totalled EUR 521.6 (April-June ...

Net sales totalled EUR 939.3 (January-June 2025: 771.0) million Operating profit was EUR 291.3 (182.5) million Basic earnings per share were EUR 1.64 (1.02) Cash flow from operating activities per ...

These people shape everything from treatment availability to insurance plans and real-world results for patients.

Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Read more ...

Evidence supports cannabis-based therapies for a limited number of conditions. Here’'s what clinicians should know — and tell ...

Cancer is among the hardest diseases to study because it is not one disease but more than 100. Breast, lung and blood cancers ...